RankAlpha logo
Back to Rankings

REVB

Revelation BiosciencesF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Starting TITAN enrollment on schedule would improve confidence in GEM-AKI execution. The company has selected a CRO, but that is not evidence that enrollment has begun.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
An August 17 executive restricted-share grant adds potential share dilution, subject to its vesting terms. [#8-K-2026-08-19] SEC filing.
Momentum
86
Value
57
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.42 · Bull $0.75 · Bear $0.18Analysis 2026-10-18; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-18 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $124.25
Why
Momentum86 · Δ7d -
Value57 · Δ7d -0.2
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Value remains the lead driver in the composite, 7D delta -0.2.

Contradictions & invalidation

  • • An August 17 executive restricted-share grant adds potential share dilution, subject to its vesting terms. [#8-K-2026-08-19] SEC filing.
  • • TITAN enrollment timing remains an objective, not a confirmed start; trial execution, safety, and results remain uncertain. [#SEC-8K-2026-08-06]
  • • Clinical-stage spending, limited runway, potential financing dilution, and Nasdaq compliance risk leave substantial downside if TITAN slips.

Catalyst clock

2026-10-20

Planned 1-for-7 reverse split

Lead driver: Value · See fundamentals
Momentum
86
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.6
Sentiment
0
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade F. Momentum 86.3 / Value 57.0 / Sentiment 0.0

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-18. Scenario method

B+
Bull case
25%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$0.42
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.18
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$2.01M
Beta
-0.11
Shares Out
569.06K
P/E (TTM) · Derived
-0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.66
Rev YoY
-
EPS YoY
-96.9%
Gross Margin
-
Op Margin
-
Net Debt
-$9.95M
Current Ratio
6.21
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data